Alzheimer ’s Drug Solanezumab Fails in Phase 3 Clinical Trial

This study was the first major Alzheimer ’s clinical trial to require molecular evidence of amyloid deposition in the brain for enrollment. While the treatment did have some favorable effects, in the main measure of outcome — measured with a cognitive test called the Alzheimer’s Disease Assessment Scale-cognitive subscale —the researchers did not observe any statistically significant benefit compared with placebo.One Good Reason To Consider an Alzheimer's Clinical TrialThe authors suggest that while it is not certain that this particular strategy or drug could be effective, it is possible that either not enough drug was administered or that the drug needs to be administered earlier in the disease course.In other studies ongoing at Columbia University Irving Medical Center and other centers, solanezumab is being evaluated in presymptomatic patients at risk of Alzheimer ’s disease. Other Alzheimer ’s drugs are also in development and being tested at higher doses.Search our Award Winning Alzheimer's Reading Room Knowledge Base for Answers to Your Questions, and Solutions to Problems“Although we are disappointed that this particular drug did not prove successful, the field is benefiting from each study,” says lead author Lawrence Honig, MD, PhD, professor of neurology at CUIMC. “There is hope that one of the newer ongoing studies may result in an effective treatment for s lowing the course of Alzheimer’s disease.”What is the Difference Between Alzheimer ’s...
Source: Alzheimer's Reading Room, The - Category: Neurology Tags: alzheimers clinical tiral alzheimers symptoms clinical trial news solanezumab Source Type: blogs